Profile of bone metastases of prostate cancer among rheumatology inpatients in Lomé (Togo): A single center experience

• Published in: Egyptian rheumatologist Vol. 36; no. 1; pp. 35 - 39
• Main Authors: Kakpovi, Kodjo, Oniankitan, Owonayo, Houzou, Prénam, Fianyo, Eyram, Koffi-Tessio, Viwalé E.S., Tagbor, Komi C., Mijiyawa, Moustafa
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.01.2014
• Subjects: Black Africa; Bone metastases; Prostate cancer; Prostate cancer; Bone metastases; Black Africa
• ISSN: 1110-1164; 2090-2433
• DOI: 10.1016/j.ejr.2013.09.003

To determine the epidemiological, clinical, paraclinical and therapeutic profile of bone metastases of prostate cancer. This was the study of a series of cases of bone metastases of prostate cancer. Fifty-eight of 2881 patients (2%) admitted to the Rheumatology department during 21years suffered from a bone metastasis of prostate cancer. The average age at admission was 64.27±8.9years while the disease duration was 28.43±44.16months. Prostate cancer was known in 27% of cases before the metastasis and the metastasis was revealing in 73% of cases. The average time between the diagnosis of prostate cancer and the development of metastasis was 5.4±3.67years in 27% of the cases. The main manifestations of patients with bone metastases were alteration of general condition (81.03%), inflammatory bone pain (75.86%), voiding disorders (58.62%) and spinal cord compression (36.20%). The spine was the main area of pain (89.65%). An osteosclerosis was the most observed radiological lesion (63.79%). The prostate specific antigen average was 301.87±738.23ng/ml. Histopathological examination was performed in 18 patients and confirmed adenocarcinoma of the prostate. Hormone therapy, mainly by anti-androgens (86.20%), surgical treatment (32.75%) and orthopedic treatment (29.31%) was administered in our patients. A severe anemia caused the death of seven patients (12.06%) during hospitalization. Diagnosis of cancer of the prostate is late and takes place in the majority of cases at the stage of metastasis.